Page 71 - Read Online
P. 71
Page 687 Gurska et al. Cancer Drug Resist 2023;6:674-87 https://dx.doi.org/10.20517/cdr.2023.39
71. Daver N, Alotaibi AS, Bücklein V, Subklewe M. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future
developments. Leukemia 2021;35:1843-63. DOI PubMed PMC
72. Marvin-Peek J, Savani BN, Olalekan OO, Dholaria B. Challenges and advances in chimeric antigen receptor therapy for acute myeloid
leukemia. Cancers 2022;14:497. DOI PubMed PMC
73. Stelmach P, Trumpp A. Leukemic stem cells and therapy resistance in acute myeloid leukemia. Haematologica 2023;108:353-66.
DOI PubMed PMC
74. Rovatti PE, Gambacorta V, Lorentino F, Ciceri F, Vago L. Mechanisms of leukemia immune evasion and their role in relapse after
haploidentical hematopoietic cell transplantation. Front Immunol 2020;11:147. DOI PubMed PMC
75. Gournay V, Vallet N, Peux V, et al. Immune landscape after allo-HSCT: TIGIT- and CD161-expressing CD4 T cells are associated
with subsequent leukemia relapse. Blood 2022;140:1305-21. DOI
76. Yan Y, Upadhyaya R, Zhang VW, Berg T. Epigenetic maintenance strategies after allogeneic stem cell transplantation in acute
myeloid leukemia. Exp Hematol 2022;109:1-10.e1. DOI PubMed
